The company operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Expansion of production capacity and supply chain automation, combined with clinical research, positions Balchem for sustained growth, operational efficiency, and premium market presence.
Cyborg Score Rationale
Profit expected to grow by a double-digit 14% over the next couple of years, the outlook is positive for Balchem. The dividend equals a 10.3% increase versus last year and marks the seventeenth consecutive annual dividend increase, which management links to sustained financial performance and board confidence in long-term strategy. The company demonstrates strong growth momentum with stable execution.
Top Insights
EU decision published on Dec 19, 2025 to impose anti-dumping duties of 90.0%–115.9% on choline chloride imports from China, providing tariff protection for Balchem's choline products
Net sales $267.6M in Q3 2025 (up 11.5% vs prior year), demonstrating consistent organic growth momentum
Seventeenth consecutive annual dividend increase reflects management confidence and consistent capital returns to shareholders
Balchem's share price may be more stable over time (relative to the market), as indicated by its low beta, offering defensive characteristics
Named Competitors
Choline/Animal Nutrition — Major choline chloride competitor with EU presence
Microencapsulation/Animal Health — Specialty ingredients for animal nutrition